Method for the continuous preparation of crystalline form II of sotagliflozin

A continuous process using toluene and xylene solutions with sodium methoxide and methanol, followed by crystallization in CSTRs, addresses the inefficiencies of traditional methods, achieving high yield and purity of crystalline Form II sotagliflozin.

JP7595064B2Active Publication Date: 2024-12-05LEXICON PHARMACEUTICALS INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2022506460
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-01
Filing Date
2020-07-31
Publication Date
2024-12-05
Estimated Expiration
2040-07-31

AI Technical Summary

Technical Problem

Current industrial processes for producing crystalline Form II of sotagliflozin face challenges such as difficulty in stirring, poor filtration, high moisture content, and formation of hard aggregates, which are not suitable for continuous production, leading to inefficiencies in yield and purity.

Method used

A continuous process using a toluene or xylene solution with sodium methoxide and methanol at controlled temperatures, followed by crystallization in a non-aqueous solvent medium, and subsequent isolation in continuous stirred-tank reactors (CSTRs), avoiding the formation of Form I and ensuring high purity and yield.

Benefits of technology

The method achieves a yield of 90% or more with 99% purity, reducing side reactions and impurities, and allows for efficient continuous production of crystalline Form II sotagliflozin.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595064000008
    Figure 0007595064000008
  • Figure 0007595064000001
    Figure 0007595064000001
  • Figure 0007595064000002
    Figure 0007595064000002
Patent Text Reader

Abstract

The present specification relates to a method for preparing crystalline form II of sotagliflozin from a compound of formula (A), the method being carried out continuously and comprising at least the following steps: a) reacting the compound of formula (A) in a toluene solution or a xylene solution, or a mixture thereof, preferably a toluene solution, with at least sodium methoxide and methanol in a reaction chamber at a temperature below the boiling point of methanol to form sotagliflozin in a mixture with a sodium salt; b) carrying out crystallization of the sotagliflozin formed in step a) in a non-aqueous solvent medium comprising at least toluene or xylene, or a mixture thereof, but not containing a sodium salt, in a crystallization chamber at the crystallization temperature of form II of sotagliflozin; and c) isolating the crystalline form II of sotagliflozin.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present specification relates to a new method for the continuous preparation of crystalline form II of sotagliflozin. [Background technology]

[0002] Sotagliflozin, also known as (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol or methyl (5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-thio-β-L-xylopyranoside, is a drug developed for the treatment of diabetes.

[0003] Today, 13 different forms of sotagliflozin have been identified, in particular two anhydrous polymorphic forms designated Class 1 and Class 4, corresponding to Form I (crude sotagliflozin) and Form II (pure sotagliflozin), respectively.

[0004] These forms, and methods for their preparation, are described inter alia in US Pat. No. 5,399,633.

[0005] Forms I and II behave like monotropic systems, with Form II being the most thermodynamically stable.

[0006] Therefore, Form II is the most interesting form of sotagliflozin.

[0007] In the current industrial process, sotagliflozin form II is produced from the methyl thioether derivative in two steps, using a mixture of methanol and water as the solvent during the first step and a mixture of methyl ethyl ketone and heptane during the second step. The first step corresponds to the synthesis, crystallization and isolation of sotagliflozin form I, and the second step corresponds to the crystallization and isolation of sotagliflozin crystalline form II.

[0008] The so obtained crystalline sotagliflozin pure form II, suspended in a methyl ethyl ketone / heptane mixture, is in the form of elongated needles. As a result, the medium at the end of crystallization is difficult to stir and the cake after filtration is insufficiently purged and contains a lot of water since it still contains 50%-60% of the solvent.

[0009] After drying, on the dry filter, sotagliflozin is in the form of very short broken needles, some forming somewhat hard agglomerates.

[0010] On an industrial scale, it would be highly advantageous to be able to carry out such a process continuously.

[0011] In fact, continuous flow synthesis offers many advantages over traditional batch synthesis since it can achieve better yields, better purity, reduced costs, and better reproducibility. [Prior art documents] [Patent documents]

[0012] [Patent Document 1] International Publication No. 2010 / 009197 Summary of the Invention

[0013] It is therefore specifically contemplated to provide such a method.

[0014] In particular, exemplary embodiments include those of formula (A): [ka] Crystalline form II of sotagliflozin from the compound: [ka] A particular method for preparing a compound according to the present invention, wherein the method is carried out continuously and comprises at least the following steps: a) reacting the compound of formula (A) in toluene or xylene or a mixture thereof, preferably in toluene, with at least sodium methoxide and methanol in a reaction chamber at a temperature below the boiling point of methanol to form sotagliflozin in a mixture with sodium salt; b) carrying out crystallization of sotagliflozin formed in step a) in a crystallization chamber in a non-aqueous solvent medium comprising at least toluene or xylene, or a mixture thereof, and not containing sodium salt, at a crystallization temperature of sotagliflozin Form II; c) isolating the crystalline form II of sotagliflozin; The present invention relates to a method comprising the steps of: [Brief description of the drawings]

[0015] [Figure 1] The crystallization temperature may be selected based on the solubility curves of sotagliflozin Form I and Form II, as shown in FIG.

[0016] "Continuous process" or "process conducted continuously" means a process that is distinct from a "batch process" and that can be continued without interruption for the supply and / or removal of products of interest.

[0017] The reaction chamber and / or crystallization chamber(s) are preferably continuous stirred-tank reactor (CSTR)(s).

[0018] Advantageously, the preparation of crystalline form II of sotagliflozin is carried out without forming crystalline form I of sotagliflozin.

[0019] The above process is particularly advantageous over the processes disclosed in the prior art as it provides Form II sotagliflozin in good yield and good chemical purity.

[0020] "Good yield" means that the said Form II sotagliflozin is obtained in a yield of 90% or more.

[0021] As used herein, "good chemical purity" is 99% or greater purity.

[0022] Indeed, said method advantageously makes it possible to achieve a clean synthesis, which is free of side reactions or decompositions leading to the production of impurities.

[0023] Formation of sotagliflozin: step a) The method comprises the step of: a) reacting the compound of formula (A) in a toluene or xylene solution or in a mixture thereof, preferably in at least a toluene solution, with at least sodium methoxide and methanol in a reaction chamber at a temperature below the boiling point of methanol to form sotagliflozin in a mixture with its sodium salt.

[0024] The boiling point of methanol at atmospheric pressure (760 mmHg) is 64.7°C.

[0025] In particular, the method comprises the step of: a) promoting the reaction of the compound of formula (A) in a toluene or xylene solution or in a mixture thereof, preferably in at least a toluene solution, with at least sodium methoxide and methanol in a reaction chamber at a temperature below the boiling point of methanol to form sotagliflozin in a mixture with its sodium salt.

[0026] By "facilitate" it is meant optimizing the conditions under which a reaction is carried out so as to favor the reaction proceeding.

[0027] In the reaction chamber, the following formula (A): [ka] Sotagliflozin is synthesized from the compound.

[0028] Prior to reaction, this compound (A) is dissolved in a non-aqueous solvent medium containing at least toluene or xylene, or a mixture thereof, preferably at least toluene.

[0029] A solution of compound (A) in 10 volumes of toluene can in particular be used.

[0030] Toluene or xylene are particularly advantageous since they allow solubilization of compound (A) and sotagliflozin.

[0031] Thus, in a preferred embodiment, a first solution of compound (A) in toluene or xylene or a mixture of toluene and xylene is prepared, which solution may be heated to completely dissolve compound (A), in particular at a temperature between 25° C. and 45° C., preferably between 30° C. and 40° C.

[0032] According to this embodiment, it is preferred to prepare a first solution of compound (A) in toluene.

[0033] The toluene content may be 5 volumes to 19 volumes, particularly 10 volumes to 19 volumes, preferably 10 volumes to 15 volumes, and more preferably 10 volumes.

[0034] For example, when the first solution of compound (A) is a toluene solution, the flow rate of the compound (A) solution in toluene in the reaction chamber can be 55 kg / h to 65 kg / h, particularly 58 kg / h to 62 kg / h.

[0035] It is understood that the flow rates of different materials in the chamber(s) may vary depending on various parameters such as, but not limited to, the volume (diameter / length) of the chamber(s) and the residence time in the chamber(s). The flow rates can be established by one of ordinary skill in the art through various routine calculations and / or experiments.

[0036] A solution of compound (A) in toluene or xylene, or in a mixture of toluene and xylene, is supplemented with a solution of sodium methoxide and methanol.

[0037] When the first solution of compound (A) is a toluene solution, the concentration of compound (A) may be contained in 10 volumes to 19 volumes of toluene, preferably equal to 10 volumes of toluene.

[0038] According to this variant, a solution of MeONa and MeOH can be prepared in which the content of MeONa is at least equal to the catalytic amount, in particular more than 0.5 equivalents, preferably more than 0.6 equivalents, and the content of MeOH is at least equal to the catalytic amount, preferably more than 12 equivalents.

[0039] In particular, the content of MeONa is a catalytic amount to 1 equivalent, particularly 0.5 equivalent to 1 equivalent, preferably 0.6 equivalent to 1 equivalent, and the content of MeOH is 12 equivalent to 20 equivalent. For example, 0.6 equivalents of MeONa and 15 equivalents of MeOH can be used.

[0040] The MeONa / MeOH solution may also be preheated before being mixed with a solution of compound (A) in toluene, xylene, or a mixture thereof.

[0041] By "catalytic amount" it is meant that a substance such as MeONa or MeOH is used in a small amount relative to the starting material, i.e., compound (A), but sufficient to effect the reaction.

[0042] For example, the flow rate of the solution of sodium methoxide and methanol in the reaction chamber may be between 3 kg / h and 8 kg / h, in particular between 4 kg / h and 6 kg / h.

[0043] According to a preferred embodiment, a solution of compound (A) in toluene or xylene or a mixture of toluene and xylene and a solution of sodium methoxide and methanol can be fed simultaneously into the reaction chamber.

[0044] A pump, such as a gear pump, membrane pump, or peristaltic pump, may be used to force the solution into the reaction chamber.

[0045] In a preferred embodiment, the temperature in step a) is below 65° C., preferably below 63° C., at atmospheric pressure.

[0046] More specifically, the reaction is carried out at atmospheric pressure and at a temperature between 60° C. and 65° C., preferably between 60° C. and 63° C. More preferably, the reaction is carried out at 60° C.

[0047] Such temperatures can be high when the reaction is carried out under high pressure, for example, at a pressure of 7-8 bar, the temperature can be around 110°C.

[0048] It is preferable to carry out this reaction under stirring.

[0049] The stirring speed can be set by one skilled in the art through various routine experiments and depends in particular on the volume of the chamber used.

[0050] The residence time in the reaction chamber is set to allow complete reaction between the compounds. The residence time can vary depending on various parameters, including but not limited to the reaction temperature, the volume (diameter / length) of the chamber, the concentration of the reacting compounds, the flow rate of the compounds into the chamber, etc. The residence time can be set by those skilled in the art through various routine experiments.

[0051] In a preferred variant, the residence time in the reaction chamber is at least 10 minutes, in particular at least 15 minutes, preferably at least 20 minutes, more preferably at least 30 minutes.

[0052] The reaction taking place in the first chamber results in the formation of a mixture comprising sotagliflozin and a sodium salt.

[0053] In a preferred variant, the reaction chamber is a continuous stirred tank reactor (CSTR).

[0054] The reaction of step a) can also be carried out in an intensified reactor.

[0055] According to this variant, the residence time in the reactor may be advantageously short, for example at least 20 seconds.

[0056] Aqueous washing and dehydration According to a preferred embodiment, the process comprises an additional step between steps a) and b) of removing sodium salts from the medium obtained at the end of step a) by aqueous washing of the medium, followed by dehydrating the medium.

[0057] This process makes it possible to remove the sodium salt formed during the reaction of the compound of formula (A) in a toluene solution, a xylene solution, or a mixture thereof with at least sodium methoxide and methanol.

[0058] Aqueous washing of the medium is preferably carried out with 0.5 to 1 volume of water.

[0059] For example, the water flow rate may be between 66 kg / h and 79 kg / h, in particular between 71 kg / h and 75 kg / h.

[0060] The temperature during the aqueous wash may be between 55° C. and 65° C., for example 60° C. Such a temperature is advantageous to avoid intermediate cooling and to prevent crystallization at this stage of the process.

[0061] This step can be carried out using a mixer / settler.

[0062] The residence time in the mixer may be at least 10 minutes, preferably at least 15 minutes.

[0063] The residence time in the settler may be at least 20 minutes, in particular at least 25 minutes, preferably at least 30 minutes, more preferably at least 40 minutes.

[0064] It is preferred that the aqueous wash be carried out under stirring.

[0065] The dehydration step is advantageous to prevent the formation of hydrates of sotagliflozin, to avoid loss of sotagliflozin in methyl acetate and / or methanol in which sotagliflozin is soluble, and to remove residual solvents such as methyl acetate and methanol, if present.

[0066] Dehydration of the medium is preferably accomplished by evaporation.

[0067] The dehydration can be carried out at atmospheric pressure or under reduced pressure.

[0068] It is preferred to evaporate at least 10% v / v, preferably 15% v / v of the solution.

[0069] Advantageously, the water content in the medium after dehydration is less than 300 ppm.

[0070] Furthermore, after evaporation, the medium is substantially free of methyl acetate and MeOH.

[0071] Preferably, when toluene is used, the concentration of the toluene solution can be adjusted to 40 g / l to 80 g / l, preferably 45 g / l to 50 g / l, more preferably 50 g / l, prior to step (b). This adjustment can be performed by adding toluene.

[0072] Crystallization: Step b) The method comprises step b) of carrying out crystallization of sotagliflozin formed in step a) in a crystallization chamber in a non-aqueous solvent medium comprising at least toluene, xylene, or a mixture thereof, preferably at least toluene, and free of sodium salt, at the crystallization temperature of sotagliflozin Form II.

[0073] By the described method, crystalline form II of sotagliflozin is directly crystallized without forming form I of sotagliflozin.

[0074] Furthermore, the loss of the synthesized crystalline form II sotagliflozin in the mother liquor is very low.

[0075] The crystallization of sotagliflozin is carried out at the crystallization temperature of sotagliflozin Form II in particular. The crystallization temperature is concentration dependent. The crystallization temperature can be selected based on the solubility curves of sotagliflozin Form I and Form II, as shown in FIG.

[0076] Preferably, step b) is carried out at atmospheric pressure and at a temperature between 60°C and 70°C, preferably between 62°C and 67°C, more preferably at 65°C.

[0077] The solution can be forced into the crystallization chamber under pressure.

[0078] In particular, when the solution contains toluene, the content of toluene used during crystallization may be 40 g / l to 80 g / l.

[0079] For example, the flow rate of the solution of sotagliflozin in the crystallization chamber can be 80 kg / hr to 90 kg / hr.

[0080] Preferably, the residence time in the crystallization chamber is at least 10 minutes, in particular at least 15 minutes, preferably at least 20 minutes, more preferably at least 30 minutes.

[0081] The crystallization is preferably carried out under stirring.

[0082] According to a preferred embodiment, the formation of sotagliflozin in crystalline form II is initiated by existing sotagliflozin in crystalline form II. Such existing sotagliflozin in crystalline form II can be synthesized, for example, according to the method described in Patent Document 1.

[0083] In particular, the formation of crystalline form II sotagliflozin can be initiated with 2% wt / w to 15% wt / w of existing form II sotagliflozin, preferably 2% wt / w to 10% wt / w of existing form II sotagliflozin.

[0084] According to this embodiment, in step b) the crystallization chamber is seeded with the existing crystalline form II of sotagliflozin.

[0085] During crystallization, it may be advantageous to use wet milling media to facilitate agitation.

[0086] According to this variant, the media obtained in the crystallization chamber is collected, subjected to wet grinding and returned to said crystallization chamber.

[0087] The crystallization chamber is preferably a continuous stirred tank reactor (CSTR).

[0088] According to a particular embodiment, step b) is carried out in two steps: in a first step, a solution of sotagliflozin is heated at atmospheric pressure to a temperature between 60° C. and 70° C., preferably between 62° C. and 67° C., preferably at 65° C. In a second step, the resulting suspension is cooled to a temperature between 20° C. and 30° C., preferably between 20° C. and 25° C., preferably at a temperature of 20° C.

[0089] Thus, according to this embodiment, the method comprises, between steps b) and (c), an additional step (b') of feeding the medium obtained at the end of step b) into a subsequent crystallization chamber at a temperature lower than the temperature of the previous crystallization chamber.

[0090] In particular, the temperature in step b') is between 20°C and 30°C, preferably between 20°C and 28°C, more preferably 20°C, at atmospheric pressure.

[0091] In this variant, wet grinding can be carried out during the first step.

[0092] According to this variant, the crystallization of sotagliflozin can be carried out in a cascade of two or more continuous stirred tank reactors.

[0093] The crystallization of sotagliflozin is preferably carried out in a cascade of two continuous stirred tank reactors.

[0094] Thus, the suspension of sotagliflozin obtained at the end of the first crystallization chamber can be pumped into the subsequent crystallization chamber, for example using a peristaltic pump.

[0095] In this variant, the residence time in the first crystallization chamber may be at least 25 minutes, preferably at least 30 minutes, and the residence time in the subsequent crystallization chamber may be at least 25 minutes, preferably at least 30 minutes.

[0096] In particular, the flow rate of the solution of sotagliflozin in the first crystallization chamber can be, for example, 80 kg / h to 90 kg / h, and the residence time in the first crystallization chamber can be at least 25 minutes, preferably at least 30 minutes. The flow rate of the suspension of sotagliflozin in the subsequent crystallization chamber can be, for example, 80 kg / h to 90 kg / h, and the residence time in the subsequent crystallization chamber can be at least 25 minutes, preferably at least 30 minutes.

[0097] Isolation of crystalline form II of sotagliflozin: step c) The method includes the step (c) of isolating sotagliflozin in crystalline form II.

[0098] Isolation of crystalline form II of sotagliflozin may be advantageously carried out at a temperature below 40°C, in particular below 30°C, preferably at 20°C.

[0099] Filtration and washing The mixture obtained after step b) or after step b') may be filtered and washed, preferably with toluene or xylene, or a mixture thereof, more preferably with toluene.

[0100] During this step the mother liquor and washes are removed.

[0101] For example, the flow rate of the suspension of sotagliflozin for filtration can be 80 kg / hr to 90 kg / hr.

[0102] In particular, the filtration of the mother liquor can be carried out at a temperature below 40°C, in particular below 30°C, preferably below 20°C.

[0103] The resulting wet cake is preferably washed with 2 volumes of toluene at 25°C.

[0104] The filtration can be carried out under vacuum or under high pressure, preferably the filtration is carried out under high pressure, for example 3 bar.

[0105] For example, filtration can be carried out on a continuous filter, such as a rotary pressure filter or a vacuum band filter.

[0106] Washing is carried out with a solvent such as toluene or xylene or a mixture thereof, preferably toluene.

[0107] Drying After filtration and washing, a drying step may be performed.

[0108] In particular, the drying step is carried out at a temperature of 45°C to 65°C, in particular 50°C to 55°C.

[0109] The drying step can be carried out under a pressure of less than 100 mbar, in particular less than 50 mbar.

[0110] In particular, the drying step may use a conical screw dryer or a pallet dryer.

[0111] calibration In particular, the calibration is carried out at a temperature between 20°C and 30°C, preferably at 25°C.

[0112] In particular, a conical sieve mill can be used.

[0113] This step makes it possible to remove clusters that may have formed during the drying step.

[0114] The present disclosure includes the embodiments described in the following sections. [Section 1] The following formula (A): TIFF0007595064000004.tif39164 Crystalline form II of sotagliflozin from the compound: TIFF0007595064000005.tif29164 20. A method for preparing a process for the preparation of a compound according to claim 1, wherein the process is carried out continuously and comprises at least the following steps: a) reacting the compound of formula (A) in toluene or xylene or a mixture thereof with at least sodium methoxide and methanol in a reaction chamber at a temperature below the boiling point of methanol to form sotagliflozin in a mixture with sodium salt; b) carrying out crystallization of sotagliflozin formed in step a) in a crystallization chamber in a non-aqueous solvent medium comprising at least toluene or xylene, or a mixture thereof, and not containing sodium salt, at a crystallization temperature of sotagliflozin Form II; c) isolating the crystalline form II of sotagliflozin; A method comprising: [Section 2] Item 3. The method according to item 1, wherein in step a), the compound of formula (A) is contained in a toluene solution. [Section 3] Item 3. The method according to item 1 or 2, wherein in step b) the non-aqueous solvent medium comprises at least toluene. [Section 4] 4. The method according to any one of items 1 to 3, wherein the temperature in step a) is less than 65° C., preferably less than 63° C. at atmospheric pressure. [Section 5] 5. The method according to any one of items 1 to 4, wherein the residence time in the reaction chamber is at least 10 minutes, in particular at least 15 minutes, preferably at least 20 minutes, more preferably at least 30 minutes. [Section 6] Item 6. The method according to any one of items 1 to 5, comprising an additional step between step a) and step (b) of removing sodium salts from the medium obtained at the end of step a) by aqueous washing of the medium, followed by dehydrating the medium. [Section 7] 7. The method of claim 6, wherein the medium is dehydrated by evaporation. [Section 8] The method according to any one of Items 1 to 7, wherein the temperature in step b) is 60° C. to 70° C., preferably 62° C. to 67° C., and more preferably 65° C. at atmospheric pressure. [Section 9] Item 9. The method according to any one of items 1 to 8, wherein in step b), the crystallization chamber is seeded with existing crystalline form II of sotagliflozin. [Section 10] Item 10. The method according to any one of items 1 to 9, wherein the residence time in the crystallization chamber is at least 10 minutes, in particular at least 15 minutes, preferably at least 20 minutes, more preferably at least 30 minutes. [Section 11] Item 11. The method according to any one of items 1 to 10, wherein the media obtained in the crystallization chamber is collected, subjected to wet grinding, and returned to the crystallization chamber. [Section 12] Item 12. The method according to any one of items 1 to 11, comprising an additional step (b') between step (b) and step (c) of feeding the medium obtained at the end of step (b) into a subsequent crystallization chamber at a temperature lower than the temperature in the previous crystallization chamber. [Section 13] Item 13. The method according to Item 12, wherein the temperature in step b') is 20°C to 30°C, preferably 20°C to 28°C, and more preferably 20°C at atmospheric pressure. [Section 14] 14. The method according to any one of items 1 to 13, wherein the mixture obtained after step b) or after step b') is subjected to filtration and washing, preferably with toluene or xylene, or a mixture thereof, more preferably with toluene. [Section 15] Item 15. The method of item 14, wherein the filtering and washing are followed by a drying step. [Section 16] Item 16. The method according to item 15, wherein the drying step is carried out at a temperature of 45°C to 65°C, particularly 50°C to 55°C. [Section 17] Item 17. The method according to any one of items 1 to 16, wherein the reaction chamber and / or crystallization chamber(s) is / are a continuous stirred tank reactor. The following examples describe the preparation of sotagliflozin Form II. These examples are not limiting and are intended only to illustrate the above method. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS EXAMPLES

[0115] Example 1: Continuous preparation method of crystalline form II of sotagliflozin with toluene Synthesis of sotagliflozin in toluene A toluene solution of compound (A) was prepared using 10 volumes of toluene at room temperature (25° C.). The medium was heated to 30° C. to 40° C. to completely dissolve compound (A).

[0116] A solution of MeONa in methanol was prepared using 0.6 equivalents of MeONa and 15 equivalents of MeOH.

[0117] Both solutions were fed at atmospheric pressure under stirring at 180 tr / min into a first reactor of continuous stirred tank type equipped with a reactor volume of 37 L. The flow rate of the toluene solution of compound (A) was 60.5 kg / h and the flow rate of the methanol solution of MeONa was 5.8 kg / h.

[0118] The synthesis was carried out at 62°C.

[0119] The residence time in the reactor was 30 minutes.

[0120] Aqueous Cleaning The resulting solution was fed to another reactor at a flow rate of 66.3 kg / hr. The aqueous wash of the reaction medium was carried out at 60°C. Washing was done with 1 volume of water / reaction medium. The sodium salts were thoroughly removed.

[0121] dehydration The solution was dehydrated in the reactor by evaporation at atmospheric pressure between 70°C and 110°C.

[0122] Crystallization Crystallization of sotagliflozin was carried out in a cascade of two continuous stirred tank reactors.

[0123] The solution was forced into the reactor by pressure.

[0124] Initially, the reactor was seeded with 7% w / w Form II sotagliflozin.

[0125] A toluene solution of sotagliflozin (50 g / l) at 65° C. was fed to the reactor at a flow rate of 84.9 kg / h while stirring at 134 tr / min. The residence time in the reactor was 30 min.

[0126] The media obtained in the crystallization chamber was collected, subjected to wet milling and returned to the crystallization chamber.

[0127] The suspension of sotagliflozin obtained at the end of the crystallization chamber was placed into another subsequent crystallization chamber.

[0128] This reactor was fed with stirring at 134 tr / min with a flow rate of 84.9 kg / h of sotagliflozin obtained at the end of the previous reactor at 20° C. The residence time in the reactor was 30 min.

[0129] The suspension obtained at the end of the reactor was collected for isolation (filtration, washing, drying).

[0130] filtration Filtration of the suspension was performed at a pressure of 2.5 bar in a rotary pressure filter at 20° C. The suspension was fed at a flow rate of 84.9 kg / h.

[0131] Washing Washing of the media was carried out at 2.5 bar pressure with 2 volumes of toluene at 20° C. The media was introduced at a flow rate of 12.5 l / h.

[0132] Drying Drying of the medium was then carried out at 55° C. under a pressure of less than 100 mbar.

[0133] Sotagliflozin Form II was crystallized in 97% yield.

[0134] XRPD (X-ray diffraction) analysis confirmed that sotagliflozin form II was obtained.

[0135] Example 2: Continuous preparation method of sotagliflozin with toluene in a boosted reactor Synthesis of sotagliflozin in toluene Sotagliflozin was synthesized in an intensive reactor at 113° C. under a pressure of 8 bar.

[0136] The reactor was fed with a solution of compound (A) in 10 volumes of toluene at a flow rate of 1194.6 g / h and a methanolic solution of MeONa (0.6 equivalents of MeONa and 15 equivalents of MeOH) at a flow rate of 114.6 g / h, both preheated to 113° C.

[0137] The residence time in the reactor was 20 seconds.

[0138] The system was maintained at a pressure of 8 bar.

[0139] Sotagliflozin was synthesized with a yield of 99.7%.

[0140] Aqueous washing, dehydration, crystallization, filtration, washing and drying were carried out according to Example 1.

[0141] XRPD (X-ray diffraction) analysis confirmed that sotagliflozin form II was obtained.

Claims

1. Formula (A): [Formula 1] Sotagliflozin in crystalline form II from the compound: [Case 2] 1. A continuous process for preparing a compound comprising the steps of: (a) reacting in a reaction chamber a compound of formula (A) in a solution of toluene, xylene, or a mixture thereof with sodium methoxide and methanol at a temperature below the boiling point of methanol to provide a medium comprising a mixture of sotagliflozin and a sodium salt; (b) crystallizing the sotagliflozin obtained in step (a) in a crystallization chamber in a non-aqueous solvent medium comprising toluene, xylene, or a mixture thereof, and not containing sodium salt, at a temperature at which sotagliflozin crystallizes as sotagliflozin crystalline form II; and (c) isolating crystalline form II of sotagliflozin The method of claim 1, further comprising the steps of:

2. 2. The method of claim 1, wherein in step (a) the compound of formula (A) is in solution in toluene.

3. 3. The process of claim 1 or 2, wherein in step (b) the non-aqueous solvent medium comprises toluene.

4. The method according to claim 1, wherein the temperature of step (a) is less than 65°C.

5. The method of claim 1, wherein the residence time in the reaction chamber is at least 10 minutes.

6. 6. The process according to any one of claims 1 to 5, comprising an additional step between steps (a) and (b) of removing sodium salts from the medium obtained at the end of step (a) by aqueous washing of said medium, followed by dehydrating said medium.

7. The method of claim 6 , wherein the medium is dehydrated by evaporation.

8. The method according to claim 1, wherein the temperature of step (b) is from 60°C to 70°C.

9. 9. The method according to any one of claims 1 to 8, wherein in step (b), the crystallization chamber is seeded with pre-existing crystalline form II of sotagliflozin.

10. The method of claim 1, wherein the residence time in the crystallization chamber is at least 10 minutes.

11. The method of claim 1, wherein the media obtained in the crystallization chamber is collected, subjected to wet grinding and returned to the crystallization chamber.

12. 12. The method according to any one of claims 1 to 11, comprising, between step (b) and step (c), an additional step (b') of feeding the medium obtained at the end of step (b) into a subsequent crystallization chamber at a temperature lower than the temperature in the previous crystallization chamber.

13. The method according to claim 12, wherein the temperature of step (b') is from 20°C to 30°C.

14. The process according to any one of claims 1 to 13, wherein the mixture obtained after step (b) or after step (b') is subjected to filtration and washing.

15. The method of claim 14, wherein the washing is with toluene, xylene, or a mixture thereof.

16. 15. The method of claim 14, wherein the filtering and washing is followed by a drying step.

17. 17. The method of claim 16, wherein the drying step is carried out at a temperature of from 45°C to 65°C.

18. The method of any one of claims 1 to 17, wherein the reaction chamber and / or crystallization chamber(s) is / are a continuous stirred tank reactor(s).

Citation Information

Patent Citations

  • Synthetic method for sotagliflozin and its analogues

    CN108912080A

  • Phlorizin analogs as inhibitors of sodium / glucose cotransporter 2

    JP2010504998A

  • Methods and compounds useful for preparing sodium-glucose cotransporter 2 inhibitors

    JP2010534661A

  • Solid form of (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol and method of use thereof

    JP2011528366A

  • A composition comprising inhibitors of sodium-glucose cotransporter 1 and sodium-glucose cotransporter 2, and a method for using the inhibitor.

    JP2014501780A